Korro Bio is trading 5.34% up at $15.08, with the rise more consistent with broader-market support than biotech-sector strength. - No clear company-specific announcement or filing dated November 2 was identified; the latest major company-specific news was October 22 preclinical data for KRRO-111. - Healthcare and biotechnology indicators were declining Monday afternoon, pointing away from a sector-wide biotech explanation.